L3VLUP
ProSign in

GILD · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GILDAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GILD
  • AMGN
010203040202120222023202420252026
Holders and value by quarter
QuarterGILDAMGN
Q3 202025 holders, $14.2bn16 holders, $16.3bn
Q4 202027 holders, $13.4bn19 holders, $14.0bn
Q1 202124 holders, $14.5bn16 holders, $14.5bn
Q2 202118 holders, $14.9bn23 holders, $13.8bn
Q3 202120 holders, $16.4bn24 holders, $11.6bn
Q4 202120 holders, $16.8bn21 holders, $10.4bn
Q1 202228 holders, $13.2bn23 holders, $9.9bn
Q2 202226 holders, $13.6bn28 holders, $9.7bn
Q3 202224 holders, $13.3bn21 holders, $7.9bn
Q4 202232 holders, $21.1bn24 holders, $9.3bn
Q1 202327 holders, $21.8bn22 holders, $8.4bn
Q2 202324 holders, $20.7bn26 holders, $7.4bn
Q3 202324 holders, $20.0bn26 holders, $8.7bn
Q4 202322 holders, $21.5bn24 holders, $8.4bn
Q1 202430 holders, $20.3bn25 holders, $6.7bn
Q2 202428 holders, $18.5bn20 holders, $8.0bn
Q3 202429 holders, $24.2bn21 holders, $8.8bn
Q4 202428 holders, $25.9bn20 holders, $8.2bn
Q1 202533 holders, $32.0bn25 holders, $12.0bn
Q2 202527 holders, $30.9bn20 holders, $10.2bn
Q3 202523 holders, $29.4bn17 holders, $10.4bn
Q4 202525 holders, $34.3bn19 holders, $18.0bn
Q1 202625 holders, $38.5bn15 holders, $21.4bn
Q2 202626 holders, $34.2bn23 holders, $24.9bn
GILD

Gilead Sciences Inc

Holders
33
Reported value
$32.0bn
Buyers
21
Sellers
12

Breadth +9 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
25
Reported value
$12.0bn
Buyers
10
Sellers
16

Breadth -6 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GILD (14)

AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, Citadel Advisors LLC, Element Capital Management LLC, ExodusPoint Capital Management LP, Holocene Advisors LP, Jane Street Group LLC, Millennium Management LLC, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP

Only AMGN (6)

ARK Investment Management LLC, Squarepoint Ops LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →